About the Healthcare Strategic Analysis Team
Geographic specific reports:
Global issue reports:

1. About This Report
   Chapter structure
   Executive summary
   Licensing trends overview
   Evolving trends in the licensing landscape
   Product licensing deals and trends
   Technology licensing deals and trends
   Bibliography
   Contributing experts
   Related reports
   Upcoming related reports

2. Executive Summary
   Strategic scoping and focus
   Key findings
   Key definitions
   Deal definitions
   Company classifications
   Explanation of launch/core/expiry analysis
   Table of Contents

3. Licensing Trends Overview
   Key findings
   Big Pharma trends
   Big Pharma's reliance on externally sourced products drives sales growth
   Big Pharma's sourcing of external products is set to grow
   AstraZeneca to become more reliant on in-licensed products as internal products face generic competition
   Abbott's recent M&A activity will reduce reliance on in-licensed products
   Pfizer's acquisition of Wyeth will see it more reliant on sales from in-licensed products
   Licensing deal trends
   Annual change in deal activity
   Big Pharma increases number of in-licensing deals during 2009
   Cash-rich Big Pharma capitalized on economic situation through second half of 2009
   Deals by subject
   The majority of Big Pharma's licensing activity focuses on deals for drug candidates
   Deals by company
   GlaxoSmithKline was the most active Big Pharma player
   GlaxoSmithKline raised its level of in-licensing activity in the second half of 2009
   Eli Lilly to focus on internal R&D capabilities rather than externally-sourced products

4. Evolving Trends in the Licensing Landscape
   Key findings
   Introduction
   Both Pharma and Biotech face the same core challenges
   Drivers and resistors of licensing
   Big Pharma's internal R&D crisis drives licensing quest
   Poor returns from Pharma's internal R&D the confounding issue
Widespread cost-saving measures and essential refocusing central to Big Pharma's streamlined R&D Biopharma's needs to collaborate are manifold
Big Pharma's cash and expertise is essential to advance Biopharma's pipeline candidates
Alliances allow companies to share the cost and inherent risks of drug development
Accessing external resources and capabilities
Future outlook for licensing deals
Big Pharma evolution
Partnership agreements become more intricate as licensees look to share development risk
How far can Big Pharma take its cost-cutting strategies?
Big Pharma's near-term focus
Late-and mid-stage deal activity set to increase as Pharma looks to offset the patent cliff
Deals with academia to multiply and become more complex
Pharma will turn increasingly to universities for early-stage innovation
Closer collaboration will reduce academic caution
Niche indications and orphan drugs are attractive licensing propositions
Smaller patient populations offset by attractive economic incentives
GlaxoSmithKline and Pfizer show greater concentration on orphan drugs
Push towards personalized medicine will shape technology deals
Strategic licensing options available for Pharma in growing diagnostics market
Big Pharma out-licensing to increase as internal R&D focus is realigned
Big Pharma divestitures could represent opportunities for smaller companies
Early-stage deal structure changes highlight Big Pharma's aversion to shouldering risk
Smaller upfront fees and additional milestone payments replace large opening values for riskier early-stage products
Option-based deals - a low-cost method of securing rights to potentially innovative early-stage products
Big Pharma's specialist external arms represent an alternative way to invest in and incorporate innovation
Big Pharma venture and option funds provide another route to team up with biotechs
GlaxoSmithKline's Centre of Excellence for External Drug Discovery focuses on option-based deals
Focus on emerging markets will increase
Regional rights sought to fuel push into emerging markets
Asia to become a key source of innovation in years to come
5. Product Licensing Deals and Trends
Key findings
Pharmaceutical licensing trends
In-licensing trends
Deals by primary goal
Research and discovery and product license deals most popular deal types for Big Pharma
Deals by therapy area
Infectious diseases is the most common therapy area for Big Pharma's product in-licensing deals
Influenza vaccine developments head anti-infective in-licensing deals
Central nervous system deals focus on the emergence of biologic treatments for Alzheimer's disease and pain
GlaxoSmithKline and Sanofi-Aventis up their focus on in-licensing oncology candidates in 2009
Deals by stage of development
Research/discovery stage products represent more than a third of all product in-licensing deals made by Big Pharma
Big Pharma moves its attention to in-licensing products at more advanced stages of development
Full license agreements form the majority of clinical stage product in-licensing deals
Marketing, promotion and distribution deals most commonly associated with marketed products
Deals by value - upfront fee paid
A premium upfront fee is standard for drug candidates that have reached Phase III development
Deals for central nervous system drugs commanded the highest upfront fees during 2008-09
Deals by drug type
Small molecules remain the main target of in-licensing deals amid increasing focus on biologics
Pfizer leads the way in stem cell therapy deals as Big Pharma generally refrains from mass investment
Deals by leading dealmakers
GlaxoSmithKline leads the field in terms of product in-licensing deals
Abbott and Roche restrict product licensing deals as attention turns to mega-merger activity
Eli Lilly, Sanofi-Aventis and Roche focus on securing the full licensing rights to a product
Johnson & Johnson ties up the greatest proportion of research and discovery deals
All Big Pharma companies in-license products across a range of therapy areas
Roche and Eli Lilly’s in-licensing deals focus on small molecules with biologic candidates largely acquired through M&A activity
GlaxoSmithKline focuses on acquiring vaccines while Sanofi-Aventis leads the way in monoclonal antibody deals
Deals by source company type
The smallest pharma/biotech companies are the source of most in-licensed products
Vast majority of deals with mid-sized and fellow Big Pharma companies are for marketing rights
Deals by region
2009 saw a significant increase in product in-licensing deals for specific regions
Asia expected to become a key source of innovation in years to come
Out-licensing trends
Deals by primary goal and region
More than half of Big Pharma’s product out-licensing deals are for marketing/promotion/distribution purposes
Leading dealmaker trends
GlaxoSmithKline and Pfizer more than double product out-licensing activity in 2009
Marketed products accounted for over half of all out-licensed products
Novartis largely out-licensed commercially-ready products for co-promotional reasons
GlaxoSmithKline divests US rights for Wellbutrin XL to Biovail for $510m
Out-licensing agreements for clinical-stage products
Innovative risk-mitigation deal struck by Eli Lilly for Alzheimer’s disease candidates
Pfizer out-licenses products following R&D prioritization
Manufacturing and supply deals
Deals by leading dealmakers
Sanofi-Aventis signed the most manufacturing/supply product agreements
Eli Lilly extends previous alliance with Amylin to include supply of a once-weekly diabetes product
Leading source companies
Lonza emerges as a key partner for Big Pharma’s outsourced manufacturing

6. Technology Licensing Deals and Trends
Key findings
Technology licensing trends
Trends in technology deals
Focus of technology
The majority of deals are for drug discovery and diagnostic technologies.

Diagnostic technology deals
Drive towards personalized medicine results in numerous deals for diagnostics
Biomarkers seen as a tool to enhance clinical development
Deals to identify companion biomarkers for cancer subtypes facilitates move towards targeted therapies

Drug discovery technologies
An array of technologies are available to increase drug discovery productivity
Sanofi-Aventis gains access to a number of biopharmaceutical discovery/development platforms
Assay/screening is high on GlaxoSmithKline's agenda
Bioinformatics software designed to improve internal efficiencies of drug development

Drug delivery technologies
Novel delivery optimization technologies focus on improving delivery of biologic drugs

Drug production technologies
Big Pharma seeks high-yielding and more cost-effective biologic production processes

Medical device technology
Johnson & Johnson's specialist subsidiaries license catheter and stent device technologies for cardiovascular diseases

Leading technology dealmakers
Johnson & Johnson signed the most technology licensing deals with its specialist subsidiaries featuring heavily
Abbott focused on diagnostic technology deals supporting its market-leader status in the field
Sanofi-Aventis sought drug discovery technologies to help identify its next generation of revenue drivers

7. Bibliography
Company press releases
Other web-based articles
Other sources
Datamonitor reports

APPENDIX
Company classification
Contributing experts
About Datamonitor
About Datamonitor Healthcare
About the Healthcare Strategic Analysis team
Geographic specific reports:
Global issue reports:
Datamonitor consulting
Disclaimer

List of Tables
Table 1: Big Pharma's influenza vaccine in-licensing deals, 2008-09
Table 2: Big Pharma's central nervous system biologics in-licensing deals, 2008-09
Table 3: Sanofi-Aventis’s oncology product in-licensing deals, 2009
Table 4: Leading central nervous system product in-licensing deals by upfront fee and value, 2008-09
Table 5: All 235 product in-licensing deals performed by the top 10 pharma companies by type, 2008-09
Table 6: Big Pharma's South and Central American product in-licensing deals, 2008-09
Table 7: Big Pharma's clinical-stage drug out-licensing deals, 2008-09
Table 8: Select diagnostic technology licensing deals made by the top 10 pharma companies, 2008-09
Table 9: Top 150 pharmaceutical companies in terms of 2008 sales

List of Figures
Figure 1: The PharmaVitae Explorer
Figure 2: Sales forecast dynamics of the top 10 pharma companies, 2009-2014
Figure 3: Top 10 pharma companies’ reliance on externally sourced products, 2002-2014
Figure 4: AstraZeneca's prescription pharmaceutical sales by source ($m), 2009-2014
Figure 5: Abbott's pre-Solvay acquisition prescription pharmaceutical sales by source ($m), 2009-2014
Figure 6: Pfizer, Wyeth, and combined Pfizer-Wyeth reliance on externally sourced products, 2002-2014
Figure 7: Licensing deals performed by the top 10 pharma companies, 2008-09
Figure 8: Licensing deals performed by the top 10 pharma companies by quarter, 2008-09
Figure 9: Subject of licensing deals performed by the top 10 pharma companies, 2008-09
Figure 10: In-licensing deals performed by the top 10 pharma companies by category, 2008-09
Figure 11: In-licensing deals performed by the top 10 pharma companies by quarter, 2008-09
Figure 12: The key drivers and resistors facing licensees and licensors in today's pharmaceutical industry
Figure 13: The growing cost of drug discovery and allocation of R&D investment by function (%), 1975-2008
Figure 14: Stage of development at signing for all 235 in-licensing product deals performed by the top 10 pharma companies, 2008-09
Figure 15: Primary goal of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 16: Therapy area focus for all 235 product in-licensing deals by the top 10 pharma companies, 2008-09
Figure 17: Therapy area focus for all 235 product in-licensing deals by the top 10 pharma companies, 2008 versus 2009
Figure 18: Big Pharma's oncology product in-licensing deals, 2008-09
Figure 19: Product in-licensing deals by stage of development at signing by the top 10 pharma companies, 2008-09
Figure 20: Comparison of product in-licensing deals by stage of development at signing by the top 10 pharma companies, 2008-09
Figure 21: Product in-licensing by stage of development at signing and primary goal by the top 10 pharma companies, 2008-09
Figure 22: Mean upfront fee value ($m) by stage of development at signing for all in-licensing product deals performed by the top 10 pharma companies, 2008-09
Figure 23: All 235 product in-licensing deals performed by the top 10 pharma companies by type, 2008-09
Figure 24: All 235 product in-licensing deals performed by the top 10 pharma companies by type and quarter, 2008-09
Figure 25: Product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 26: Primary goal of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 27: Stage of development of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 28: Therapy area of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 29: Product type of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 30: Biologic product in-licensing deals performed by the top 10 pharma companies by type, 2008-09
Figure 31: Source company of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 32: Source company and primary goal of all 235 product in-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 33: Product in-licensing deals performed by the top 10 pharma companies by region, 2008-09
Figure 34: Primary goal of all 94 product out-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 35: Product out-licensing deals performed by the top 10 pharma companies, 2008-09
Figure 36: All 94 product out-licensing deals performed by the top 10 pharma companies by stage of development, 2008-09
Figure 37: Novartis's key ex-US out-licensing regional co-promotion deals, 2008-09
Figure 38: All 17 manufacturing and supply licensing deals performed by the top 10 pharma companies, 2008-09
Figure 39: Application of different technology types across the drug development process
Figure 40: Focus of all 133 technology licensing deals performed by the top 10 pharma companies, 2008-09
Figure 41: Breakdown of drug discovery technology licensing deals performed by the top 10 pharma companies, 2008-09
Figure 42: The role of drug delivery technologies in a drug's lifecycle
Figure 43: Focus of all 133 technology licensing deals performed by the top 10 pharma companies, 2008-09

Related Reports:
The Healthcare Packaging Market 2011-2021
Angioedema Global Clinical Trials Review, Q1, 2011
Radiculopathy Global Clinical Trials Review, Q1, 2011
Movement Disorders Global Clinical Trials Review, Q1, 2011
Musculoskeletal Pain Global Clinical Trials Review, Q1, 2011
Fragile X Syndrome Global Clinical Trials Review, Q1, 2011
Lupus Nephritis Global Clinical Trials Review, Q1, 2011
Dysphagia Global Clinical Trials Review, Q1, 2011
Skin Rash Global Clinical Trials Review, Q1, 2011
Will 2011 Spell a Brighter Year for the Pharmaceutical Companies?